GLP-1 Therapy: What It Actually Does to Your Hormones, Gut, and Metabolism
Why This Conversation Matters Right Now
If you're considering or already taking a GLP-1 medication such as semaglutide (Ozempic, Wegovy) or tirzepatide (Zepbound, Mounjaro), you've probably heard plenty about weight loss—and much less about everything else these medications affect.
GLP-1 therapy interacts with multiple systems throughout the body, including the gut, muscle mass, micronutrient status, hormones, and metabolism. These effects matter whether you're a woman navigating a hormonal transition such as perimenopause, a man addressing low testosterone, or simply someone working toward better metabolic health.
IVY Integrative does not prescribe GLP-1 medications, but many of our patients are already taking one, considering one, or navigating its effects. Understanding what is happening in your body during GLP-1 therapy can help you make informed decisions and build a more comprehensive approach to your health.
How GLP-1 Medications Work
GLP-1 medications work by mimicking a hormone your body naturally produces. Glucagon-like peptide-1 (GLP-1) is released by the intestines in response to food and plays an important role in regulating appetite, digestion, blood sugar, and metabolism. GLP-1 receptor agonists amplify this pathway, which is why their effects extend well beyond appetite and weight.
One of the most important effects of GLP-1 therapy is slowed gastric motility. In other words, the medication slows how quickly food moves through the digestive system. The nausea, early fullness, and gastrointestinal slowdown some patients experience aren't necessarily incidental side effects—they are related to the way GLP-1 affects gastric and intestinal motility.
For some individuals, this can become clinically significant and contribute to delayed gastric emptying or gastroparesis. This matters not only for digestive comfort but also for how nutrients and other medications are absorbed.
There is also an important relationship between GLP-1 and the gut microbiome. Your existing gut microbial composition may influence how much GLP-1 your body produces naturally and how you respond to GLP-1 therapy. At the same time, GLP-1 receptor agonists can influence the composition of the gut microbiome during treatment. This two-way relationship is an active area of research and an important consideration when looking at GLP-1 therapy through a whole-person lens.
GLP-1 Therapy and Hormones: It's Not Just About Estrogen
Weight loss can influence hormone status in both women and men, and GLP-1 therapy is increasingly being studied in connection with a variety of hormone-related conditions.
For women, hormonal transitions such as perimenopause can independently influence fat distribution and insulin sensitivity. These changes are part of the reason GLP-1 therapy in perimenopausal and postmenopausal women has become an active area of research.
For men, low testosterone and excess adiposity can influence one another. Obesity can lower free testosterone through several mechanisms, including increased conversion of testosterone to estrogen in fat tissue and changes to the hypothalamic-pituitary-gonadal axis.
The relationship can work in the other direction as well. Weight loss, including weight loss associated with GLP-1 therapy, has been shown to increase testosterone levels in some men with hypogonadism. For men whose low testosterone is related to excess weight rather than a primary testicular or pituitary condition, meaningful fat loss may be an important part of the conversation around metabolic and hormonal health.
Why Muscle Mass Matters During GLP-1 Therapy
When we talk about GLP-1 therapy, the conversation often centers around how much weight someone loses. But the number on the scale doesn't tell the whole story.
Skeletal muscle is one of the body's largest sites for insulin-mediated glucose disposal and plays an important role in resting metabolic rate. Maintaining muscle supports healthy blood sugar regulation, insulin sensitivity, strength, and metabolic health.
This is particularly important because weight loss can include both fat mass and lean mass. When muscle is lost along with fat, some of the metabolic benefits we're trying to achieve can be undermined.
Muscle preservation deserves particular attention for people who may already be at increased risk of muscle loss, including aging adults and women during and after perimenopause. Resistance training and adequate protein intake can play an important role in preserving muscle during GLP-1 therapy and are worth incorporating into a plan from the beginning—not only after muscle loss has already occurred.
Beyond Weight Loss: Other Potential Uses for GLP-1 Therapy
Weight management gets most of the attention, but GLP-1 receptor agonists are also being studied and used in connection with other metabolic and hormone-related conditions.
Polycystic ovary syndrome (PCOS) is one area of interest. Because insulin resistance is a central component of PCOS for many women, GLP-1 therapy is being studied for its potential effects on insulin resistance, weight management, and ovulatory function.
GLP-1 receptor agonists are also being studied for metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease (NAFLD). Research suggests these medications may help reduce liver fat and inflammation as part of a broader approach to metabolic health.
If you're managing PCOS or fatty liver disease, GLP-1 therapy may be worth discussing with your prescribing provider as one potential component of your treatment options.
What an Integrative Approach Can Add to GLP-1 Therapy
Whether you're currently taking a GLP-1 medication, considering one, or choosing a different path altogether, an integrative approach can look beyond the prescription itself.
This may include monitoring relevant nutrients and metabolic markers, developing a resistance-training and protein strategy that fits your lifestyle, and addressing digestive health and gut function throughout treatment. Depending on the individual, an integrative evaluation may also consider iron and ferritin, vitamin B12, vitamin D, thyroid markers, fasting glucose and insulin, and sex hormones.
Nutrition deserves particular attention during GLP-1 therapy. When appetite and food intake decrease, it can become more difficult to consistently consume enough protein and essential nutrients. Reduced intake combined with slowed digestion may increase the risk of nutritional gaps over time.
Gut-directed support can also be important. Because GLP-1 medications influence gastrointestinal motility, individualized support may focus on digestion, motility, bile flow, and the gut microbiome based on a person's symptoms and treatment needs.
And what happens when you eventually stop the medication matters, too. Weight regain after GLP-1 discontinuation is common, which is why developing sustainable nutrition, movement, and lifestyle habits during treatment can be an important part of the long-term picture. Any changes to medication should be coordinated with your prescribing provider.
The goal isn't to talk you into or out of GLP-1 therapy. It's to make sure that whatever path you're taking is supported at the level your body needs—from the time you start treatment through the time you eventually transition off of it.
The Bottom Line
GLP-1 medications can be a useful tool for many people and conditions, but they don't operate in isolation. They interact with the gut, muscle mass, micronutrient status, hormones, and metabolism.
A whole-person approach considers these systems together rather than focusing solely on the number on the scale. Supporting nutrition, muscle health, digestion, hormones, and metabolic health throughout GLP-1 therapy may help create a more comprehensive and sustainable approach to your overall wellness.
Looking for Support During GLP-1 Therapy?
Taking a GLP-1 medication, considering one, or wondering whether it's the right approach for you?
Book a FREE 15-minute meet and greet to learn how personalized functional and integrative care may help support your gut health, hormones, muscle health, nutrition, and metabolic wellness throughout your GLP-1 journey.
Author: Dr. Marissa Boyd, ND
References
Kling JM, et al. “GLP-1 Receptor Agonists for Weight Loss for Perimenopausal and Postmenopausal Women: Current Evidence.” Current Opinion in Obstetrics and Gynecology, 2025.
Comninos AN, Jayasena CN. “Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) for Obesity and Symptoms in Menopause: A Review.” Cureus, 2026.
Deane AM, et al. “GLP-1 Regulates Gastroduodenal Motility Involving Cholinergic Pathways.” Neurogastroenterology & Motility, 2009.
Hellström PM, et al. “GLP-1 Suppresses Gastrointestinal Motility and Inhibits the Migrating Motor Complex in Healthy Subjects and Patients with Irritable Bowel Syndrome.” Neurogastroenterology & Motility, 2008.
Krishnan B, et al. “GLP-1 Receptor Agonists and Delayed Gastric Emptying: Implications for Invasive Cardiac Interventions and Surgery.” Cardiovascular Endocrinology & Metabolism, 2024.
Grasset E, et al. “Crosstalk Between Glucagon-Like Peptide 1 and Gut Microbiota in Metabolic Diseases.” mBio, 2024.
“GLP-1 Agonists and the Gut Microbiome: A Bidirectional Relationship.” British Journal of Clinical Pharmacology, 2026.
Camacho EM, et al. “Weight Loss More Than Glycemic Control May Improve Testosterone in Obese Type 2 Diabetes Mellitus Men with Hypogonadism.” Andrology, 2020.
Merz KE, Thurmond DC. “Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake.” Comprehensive Physiology, 2020.
Prado CM, et al. “Changes in Lean Body Mass with GLP-1-Based Therapies and Mitigation Strategies.” Diabetes, Obesity & Metabolism, 2024.
Jensterle M, et al. “Update on the Effects of GLP-1 Receptor Agonists for the Treatment of Polycystic Ovary Syndrome.” Expert Review of Clinical Pharmacology, 2021.
“The Dual Impact of GLP-1 Receptor Agonists on Metabolic and Reproductive Health in Polycystic Ovary Syndrome: Insights from Human and Animal Trials.” Therapeutic Advances in Endocrinology and Metabolism, 2026.
“Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials.” Metabolites, 2021.
“Therapeutic Effects of Glucagon-like Peptide-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: A Systematic Review.” International Journal of Molecular Sciences, 2025.
“Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy: A Narrative Review.” Clinical Obesity, 2025.
“Ironing Out Possible Micronutrient Def
Disclaimer:
This information is generalized and intended for educational purposes only. Due to potential individual contraindications, please see your primary care provider before implementing any strategies in these posts.
